Zymo Research Makes Strategic Investment in Star range to Develop an A…
IRVINE, Calif., April 27, 2022 /PRNewswire/ — Zymo Research and Star range today announced Zymo Research’s strategic investment to acquire an interest in Star range, a privately owned, biomedical technology company based in Singapore. The investment allows Zymo Research and Star range to combine Zymo Research’s nucleic acid purification and assay technologies with Star range’s engineering and automation skill to expand into emerging For Research Use Only (FRUO) and diagnostic markets including Point-of-Care testing (POCT).
Star range’s focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology. It manufactures and markets various genetic analyzers including its premier product, XDive™, a superfast qPCR platform, with related kits and software. During the COVID-19 sudden increase, Star range developed a test for SARS-CoV-2 detection employing its XDive™ system. The complete course of action from sample-to-answer takes less than 45 minutes and the system can be used in any clinical ecosystem. Star range is currently working by the Emergency Use Authorization (EUA) course of action with the U.S. Food and Drug Administration (FDA) by the National Institutes of Health (NIH) Rapid speeding up of Diagnostics (RADx®) program.
Zymo Research, since its inception in 1994, is well known for its DNA/RNA extraction and assay technologies. Its goal has been to develop more efficient sample collection kits and devices that simplify and reduce the time needed to isolate nucleic acids in the laboratory. Zymo Research will be partnering with Star range to develop ready-made cassettes containing the necessary reagents for Star range’s COVID-19 test kit in addition as future POCT.
“Star range’s powerful PCR instrumentation places them at the spotlight of PCR technology with their XDive™ PCR system that can complete a typical 40-cycle multiplex qPCR run in 5-7 minutes. When coupled with Star range’s system, Zymo Research’s DNA/RNA purification reagents and nucleic acid-based assays will ease a straightforward Sample-In/Answer-Out workflow. by our investment in Star range we will develop products targeting POCT in the global marketplace,” said Marc Van Eden, Vice President of Business Development at Zymo Research.
“Zymo Research and Star range have both built businesses at the intersection of science and technology and we proportion a vision of ultrafast PCR technology that will permit POC PCR tests to be analyzed in just minutes in doctor’s offices, laboratories, and hospitals. Together we strive to build already more POCT products in the future,” said Dr. Yanhui Liu, Vice President of Star range Pte. Ltd.
To learn more about Zymo Research’s DNA/RNA extraction and assay technologies visit their website. For more information about Star range’s technology, click here:
About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific and diagnostics community with state-of-the-art molecular biology tools since 1994. The company’s vision “The Beauty of Science is to Make Things Simple” is reflected in all of its products, from epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, diagnostic devices, and Next-Generation Sequencing (NGS) technologies that are high quality and simple to use. Follow Zymo Research on Facebook, LinkedIn, Twitter, and Instagram.
About Star range Pte Ltd
Star range is a leading developer of super-fast on-site genetic testing based on novel integrated sample preparation and qPCR processes. The company focuses on superfast nucleic acid amplification and extraction technologies. The need for rapid response time has led Star range to introduce superfast genetic testing for on-site accuracyn treatment in doctor’s offices and routine laboratory testing in hospitals. Star range is headquartered in Singapore. Contact Star range at
This Press Release has not been vetted or endorsed by The Eastern Herald‘s editorial staff. No oligarch or politician dictates to us how to write about any subject. We need your sustain. Please contribute at all event you can provide. Click here to make your donation.
Click: See details